New diabetes drug enters final testing phase
NCT ID NCT07060456
Summary
This study aims to see if a new drug called HRS9531 works better than a placebo (inactive substance) at lowering blood sugar in adults with type 2 diabetes. It is for people whose blood sugar is still not well controlled even while taking a long-acting insulin. About 300 participants will take either HRS9531 or a placebo for 40 weeks to compare results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Perking University Peoples' Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact
Conditions
Explore the condition pages connected to this study.